Lv36
310 积分 2024-03-04 加入
Comparing available criteria for measuring brain metastasis response to immunotherapy
1天前
待确认
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
7天前
已完结
https://ascopubs.org/doi/10.1200/JCO.2012.44.2806?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
7天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
8天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
8天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
1个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
2个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
2个月前
已完结
皖公网安备34019202002308
